Enliven Therapeutics: Preclinical Company With Interesting Value Proposition (NASDAQ:ELVN)

andreswd/E+ by way of Getty Pictures

Largely talking, each different early stage biopharma I cowl begins out with a candidate focusing on some type of leukemia/lymphoma. Right here’s yet another so as to add to that checklist – Enliven Therapeutics, Inc. (NASDAQ:ELVN) – a

Back To Top